Content
All Posts > Content under Healthcare
Market Briefing For Friday, March 24
Article By:
Gene Inger
Read
Friday, March 24, 2017 9:22 AM EDT
As of early Thursday evening there was talk of no Healthcare vote until Monday, with nothing brought to the House Floor as of yet.
Sanofi To Buy Flexion Therapeutics, Inc. For +$1 Billion In Cash
Article By:
Lorimer Wilson
Read
Thursday, March 23, 2017 6:04 PM EDT
Sanofi is in talks to buy Flexion Therapeutics, Inc. a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in cash, according to a source close to the deal.
Market Briefing For Thursday, March 23
Article By:
Gene Inger
Read
Thursday, March 23, 2017 2:22 PM EDT
The Healthcare Bill still looks destined for a down-vote. If they can either pass it or defer it, fine for markets having a prospect to rebound. If not you have a problem for the market coming up rather soon.
Ultragenyx Pharmaceutical Inc. Drug "UX007" Fails Phase II Trial - Stock Tumbles
Article By:
Lorimer Wilson
Read
Thursday, March 23, 2017 1:23 PM EDT
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases reported that its drug UX007 failed a Phase II trial causing its stock to plummet.
In this article: RARE
Ultragenyx Pharmaceutical Inc. Shares Fall As Seizure Drug Fails Study
Article By:
TickerTV
Read
Thursday, March 23, 2017 12:31 PM EDT
RARE opened trading yesterday at $77.73 which was up from the previous day’s trading close of $77.72. Shares closed trading yesterday at $78.36 and spiked down after market to $73.20, equivalent to a 7% decrease from the closing price.
In this article: RARE
Teva Pharmaceutical Industries Ltd. In Turmoil, Plans To Cut 11% Of Its Workforce After Passover
Article By:
Lorimer Wilson
Read
Thursday, March 23, 2017 10:17 AM EDT
With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm, TEVA is reportedly preparing to unleash a major reorganization that will cost thousands of jobs.
Global Stocks, US Futures Rebound Ahead Of Critical Obamacare Repeal Vote, Yellen Speech
Article By:
Tyler Durden
Read
Thursday, March 23, 2017 7:18 AM EDT
European and Asian stocks were modestly in the green, with U.S. futures higher, before a critical procedural vote on a Republican health-care bill to repeal Obamacare, while Janet Yellen is set to speak in Washington at 8:45am.
Fosamax Claims Come Back To Haunt Merck & Co., Inc
Article By:
Lorimer Wilson
Read
Thursday, March 23, 2017 6:35 AM EDT
Merck probably thought that long-dormant legal claims about previously undisclosed risks associated with its osteoporosis drug Fosamax were dead and buried but those decades-old claims have been revived again by a major court decision on Wednesday.
In this article: MRK
3 ETF Charts Showing Red Flags
Article By:
David Fabian
Read
Thursday, March 23, 2017 4:22 AM EDT
XLE peaked in December 2016 and has been on a slow descent ever since.This index also just recently crossed below its long-term 200-day moving average, which may indicate the start of a new downtrend as crude oil prices touch new year-to-date lows.
Thursday's Defining Moment: Defeat Obamacare Lite Or Be Buried By The Welfare State
Article By:
David Stockman
Read
Wednesday, March 22, 2017 5:26 PM EDT
Thursday's vote on Speaker Ryan's wrong-headed plan to repeal and replace Obamacare involves far more than keeping faith with a crucial campaign pledge or the Donald's notion that it's just the preliminaries to "cutting the hell out of taxes".
Swing Trade Setups To Watch
Article By:
Ryan Mallory
Read
Wednesday, March 22, 2017 1:37 PM EDT
Something broke in the market yesterday and that a 5% or worse of a pullback is in store for the market, so that probably means that the bulls will be trying to hit new all-time highs before the lunch hour approaches.
Why I'm Long Shares Of HedgePath Pharma
Article By:
Jason Napodano
Read
Wednesday, March 22, 2017 12:44 PM EDT
HedgePath remains an attractive story for small-cap biotech investors. The company is likely to report positive top-line Phase 2b results during the first half of 2017.
In this article: HPPI
